Substance / Medication

Nintedanib esilate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Exposure-Efficacy Meta-Model of Nintedanib in Adult Patients With Chronic Fibrosing Interstitial Lung Diseases.
Hartmann Sonja, Janssen Julie, Ribbing Jakob et al. · CPT Pharmacometrics Syst Pharmacol · 2026
PMID: 41268834Meta-AnalysisFull text (PMC)
Transcriptomics of interstitial lung disease: a systematic review and meta-analysis.
He Daniel, Guler Sabina A, Shannon Casey P et al. · Eur Respir J · 2025
PMID: 39603671Meta-AnalysisFull text (PMC)
Health-related quality of life and health state utility value in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
Zhao Guixiang, Lei Siyuan, Li Ya et al. · Health Qual Life Outcomes · 2025
PMID: 39757157Meta-AnalysisFull text (PMC)
Lack of diversity in antifibrotic trials for pulmonary fibrosis: a systematic review.
Pascoe Amy, Chen Xinye Esther, Smallwood Natasha · Eur Respir Rev · 2025
PMID: 40044188Meta-AnalysisFull text (PMC)
Baseline total lung capacity and all-cause mortality in restrictive pulmonary disorders: a meta-analysis.
Li Fei, Chen Yifan, Zhang Guozhou et al. · BMC Pulm Med · 2025
PMID: 40055715Meta-AnalysisFull text (PMC)
The 6 Minute Walk Test as a predictor of mortality in idiopathic pulmonary fibrosis: A systematic review.
Vecchi Eugenio, Kilbey Timothy, Sheth Mihir et al. · Respir Investig · 2025
PMID: 40081204Meta-Analysis
Comorbidities in the idiopathic pulmonary fibrosis and progressive pulmonary fibrosis trial population: a systematic review and meta-analysis.
Walters Tyson M, Leong Marcus C H, Montesi Sydney B et al. · Eur Respir Rev · 2025
PMID: 40107663Meta-AnalysisFull text (PMC)
Diagnosis accuracy of machine learning for idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
Cong Li, Chen Ying, He Xiaolei et al. · Eur J Med Res · 2025
PMID: 40235000Meta-AnalysisFull text (PMC)
A Systematic Review of Mortality Risk Prediction Models for Idiopathic Pulmonary Fibrosis.
Wu Yingxu, Li Pin, Wang Mei et al. · Br J Hosp Med (Lond) · 2025
PMID: 40265534Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Nintedanib esilate (substance)
SNOMED CT
863993005
UMLS CUI
C3529778

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.